AstraZeneca, Daiichi breast cancer drug set for speedy FDA review
Bio Pharma Dive
JULY 25, 2022
The agency agreed to quickly assess the companies’ drug Enhertu for “HER2 low” metastatic breast cancer, an indication for which it could become the first targeted treatment option.
Let's personalize your content